Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms

  • Authors:
    • Songtao Qi
    • Lei Yu
    • Hezhen Li
    • Yanghui Ou
    • Xiaoyu Qiu
    • Yanqing Ding
    • Huixia Han
    • Xuelin Zhang
  • View Affiliations

  • Published online on: March 28, 2014     https://doi.org/10.3892/ol.2014.2013
  • Pages: 1895-1902
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The molecular subsets of glioma behave in biologically distinct ways. The present study detected isocitrate dehydrogenase (IDH) 1 and IDH2 mutations in glioma to analyze whether IDH‑mutated gliomas are situated in certain preferential areas and to investigate their correlation with magnetic resonance imaging (MRI) characteristics. A series of 193 patients with astrocytic neoplasms (111 diffuse and 82 anaplastic astrocytomas), grouped according to prelabeled anatomical structures and the risk of surgery, were retrospectively reviewed for IDH1 and IDH2 mutations to compare the tumor location and MRI features. A total of 111 IDH1 mutations at codon 132 (57.5%) and six IDH2 mutations at codon 172 (3.1%) were detected. The IDH1/2 mutations were found to predict longer survival, independent of the histological type in this series of patients. The IDH‑mutated gliomas were predominantly located in a single lobe, such as the frontal lobe, temporal lobe or cerebellum and rarely in the diencephalon or brain stem. Furthermore, according to the risk of surgery, the IDH‑mutated tumors were rarely located in the high‑risk regions of the brain, where surgery exhibits a high mortality rate intraoperatively and postoperatively. In addition, gliomas with IDH mutations were significantly more likely to exhibit a unilateral pattern of growth, sharp tumor margins, homogeneous signal intensity and less contrast enhancement on MRI. The results of the current study suggested that the prolonged survival of patients with IDH‑mutated gliomas is primarily due to a less aggressive biological behavior according to tumor site and MRI features.

References

1 

Xu BJ, An QA, Srinivasa GS, et al: Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma. Int J Oncol. 40:1995–2003. 2012.

2 

Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI

3 

Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C and von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116:597–602. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Hartmann C, Meyer J, Balss J, et al: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 118:469–474. 2009. View Article : Google Scholar

5 

Ichimura K, Pearson DM, Kocialkowski S, et al: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 11:341–347. 2009. View Article : Google Scholar : PubMed/NCBI

6 

Watanabe T, Nobusawa S, Kleihues P and Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 174:1149–1153. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Nobusawa S, Watanabe T, Kleihues P and Ohgaki H: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 15:6002–6007. 2009. View Article : Google Scholar : PubMed/NCBI

9 

Sanson M, Marie Y, Paris S, et al: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 27:4150–4154. 2009. View Article : Google Scholar : PubMed/NCBI

10 

Toedt G, Barbus S, Wolter M, et al: Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer. 128:1095–1103. 2011. View Article : Google Scholar : PubMed/NCBI

11 

Qi ST, Yu L, Lu YT, et al: IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. Oncol Rep. 26:1479–1485. 2011.

12 

Reitman ZJ and Yan H: Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 102:932–941. 2010. View Article : Google Scholar : PubMed/NCBI

13 

Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ and van den Bent MJ: Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol. 12:83–91. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Labussiere M, Sanson M, Idbaih A and Delattre JY: IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? Oncologist. 15:196–199. 2010. View Article : Google Scholar : PubMed/NCBI

15 

Zou P, Xu H, Chen P, et al: IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One. 8:e687822013. View Article : Google Scholar : PubMed/NCBI

16 

Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Reed GH, Kent JO and Wittwer CT: High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics. 8:597–608. 2007. View Article : Google Scholar : PubMed/NCBI

18 

Dang L, Jin S and Su SM: IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med. 16:387–397. 2010. View Article : Google Scholar : PubMed/NCBI

19 

Yen KE, Bittinger MA, Su SM and Fantin VR: Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 29:6409–6417. 2010. View Article : Google Scholar : PubMed/NCBI

20 

Metellus P, Coulibaly B, Colin C, et al: Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 120:719–729. 2010. View Article : Google Scholar : PubMed/NCBI

21 

Persson AI, Petritsch C, Swartling FJ, et al: Non-stem cell origin for oligodendroglioma. Cancer Cell. 18:669–682. 2010. View Article : Google Scholar : PubMed/NCBI

22 

Ohgaki H and Kleihues P: Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 100:2235–2241. 2009. View Article : Google Scholar : PubMed/NCBI

23 

Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI

24 

Zlatescu MC, TehraniYazdi A, Sasaki H, et al: Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 61:6713–6715. 2001.PubMed/NCBI

25 

Mueller W, Hartmann C, Hoffmann A, et al: Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol. 161:313–319. 2002. View Article : Google Scholar : PubMed/NCBI

26 

Huang L, Jiang T, Yuan F, Li GL, Liu EZ and Wang ZC: Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors. Clin Neurol Neurosurg. 110:1020–1024. 2008. View Article : Google Scholar : PubMed/NCBI

27 

Laigle-Donadey F, Martin-Duverneuil N, Lejeune J, et al: Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology. 63:2360–2362. 2004. View Article : Google Scholar : PubMed/NCBI

28 

Gozé C, Rigau V, Gibert L, Maudelonde T and Duffau H: Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis? J Neurooncol. 91:1–5. 2009.PubMed/NCBI

29 

Eoli M, Bissola L, Bruzzone MG, et al: Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer. 119:84–90. 2006. View Article : Google Scholar : PubMed/NCBI

30 

Eoli M, Menghi F, Bruzzone MG, et al: Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res. 13:2606–2613. 2007. View Article : Google Scholar : PubMed/NCBI

31 

Drabycz S, Roldán G, de Robles P, et al: An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage. 49:1398–1405. 2010. View Article : Google Scholar : PubMed/NCBI

32 

Megyesi JF, Kachur E, Lee DH, et al: Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res. 10:4303–4306. 2004. View Article : Google Scholar : PubMed/NCBI

33 

Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC and Walker C: Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain. 129:1884–1891. 2006. View Article : Google Scholar : PubMed/NCBI

34 

Jenkinson MD, Smith TS, Brodbelt AR, Joyce KA, Warnke PC and Walker C: Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype. J Magn Reson Imaging. 26:1405–1412. 2007. View Article : Google Scholar : PubMed/NCBI

35 

Jenkinson MD, Smith TS, Joyce KA, et al: Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology. 48:703–713. 2006.PubMed/NCBI

36 

Walker C, du Plessis DG, Fildes D, et al: Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res. 10:7182–7191. 2004. View Article : Google Scholar : PubMed/NCBI

37 

Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN and Barker FN II: Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res. 11:8600–8605. 2005. View Article : Google Scholar

38 

van den Bent MJ, Dubbink HJ, Marie Y, et al: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 16:1597–1604. 2010.

39 

Dubbink HJ, Taal W, van Marion R, et al: IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology. 73:1792–1795. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2014
Volume 7 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Qi, S., Yu, L., Li, H., Ou, Y., Qiu, X., Ding, Y. ... Zhang, X. (2014). Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncology Letters, 7, 1895-1902. https://doi.org/10.3892/ol.2014.2013
MLA
Qi, S., Yu, L., Li, H., Ou, Y., Qiu, X., Ding, Y., Han, H., Zhang, X."Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms". Oncology Letters 7.6 (2014): 1895-1902.
Chicago
Qi, S., Yu, L., Li, H., Ou, Y., Qiu, X., Ding, Y., Han, H., Zhang, X."Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms". Oncology Letters 7, no. 6 (2014): 1895-1902. https://doi.org/10.3892/ol.2014.2013